Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESTINY-Lung04 first-line trastuzumab deruxtecan versus platinum-pemetrexed-pembrolizumab in HER2-mutant advanced NSCLC
NL-OMON52083Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Mar 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of trastuzumab deruxtecan in non-small cell lung cancer (NSCLC) (2 arms), sponsored by AstraZeneca. Primary endpoint: Progression-free survival by blinded independent central review. Started Mar 2022; status: recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON52083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52083.